| Market cap | $226.08M |
|---|---|
| Enterprise value | N/A |
| Revenue | $18.358M |
|---|---|
| EBITDA | N/A |
| Income | -$163.41 |
| Revenue Q/Q | -88.07% |
| Revenue Y/Y | -74.21% |
| P/E | 0.00 |
|---|---|
| Forward P/E | N/A |
| EV/Sales | 2.78 |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| PEG | N/A |
| Price/Sales | 12.32 |
| P/FCF | N/A |
| Price/Book | 5.72 |
| Book/Share | 0.15 |
| Cash/Share | 0.58 |
| FCF yield | -61.03% |
| Volume | 2.783M / 1.642M |
|---|---|
| Relative vol. | 1.69 × |
| EPS | N/A |
|---|---|
| EPS Q/Q | -20.00% |
| Est. EPS Q/Q | 0.00% |
| Profit margin | -188.90% |
|---|---|
| Oper. margin | -1,038.56% |
| Gross margin | 100.00% |
| EBIT margin | -883.39% |
| EBITDA margin | -4,599.77% |
| Ret. on assets | -55.38% |
|---|---|
| Ret. on equity | -234.56% |
| ROIC | -36.80% |
| ROCE | -84.64% |
| Debt/Equity | 6.15 |
|---|---|
| Net debt/EBITDA | 7.00 |
| Current ratio | 2.81 |
| Quick ratio | 2.81 |
| Volatility | 8.29% |
|---|---|
| Beta | 1.20 |
| RSI | 31.98 |
|---|
| Insider ownership | 0.17% |
|---|---|
| Inst. ownership | 70.53% |
| Shares outst. | 154.661M |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.00% |
| Short ratio | 4.86 |
| Dividend | N/A |
|---|---|
| Dividend yield | N/A |
| Payout ratio | N/A |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 8 Aug 2024 |
Friday, 12 April 2024
|
|
| Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated | |
Wednesday, 6 March 2024
|
|
| Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates | |
Tuesday, 31 October 2023
|
|
| Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS | |
| Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control | |
Monday, 11 September 2023
|
|
| Dr. Karen Chagin Joins Adaptimmune as Senior Vice President of Early-Stage Development | |
Wednesday, 9 August 2023
|
|
| Adaptimmune Reports Second Quarter Financial Results and Business Update | |
Thursday, 1 June 2023
|
|
| Adaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company | |
Thursday, 25 May 2023
|
|
| Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO | |
Monday, 6 March 2023
|
|
| Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company | |
Thursday, 16 February 2023
|
|
| Adaptimmune Announces Changes to Board of Directors | |
Sunday, 8 January 2023
|
|
| Even after rising 48% this past week, Adaptimmune Therapeutics shareholders are still down 72% over the past five years | |
Friday, 18 November 2022
|
|
| Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent | |
Friday, 1 July 2022
|
|
| Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket | |
Monday, 11 April 2022
|
|
| Why Adaptimmune Therapeutics Shares Dropped 14.7% on Monday | |
Wednesday, 19 January 2022
|
|
| 2 Cancer Stocks With Absurdly Low Valuations | |
Saturday, 4 December 2021
|
|
| Here's Why Biotech Stocks Adaptimmune Therapeutics, Agenus, and Ocugen All Crashed in November | |
Thursday, 18 November 2021
|
|
| 2 Falling-Knife Stocks Actually Worth Buying Right Now | |
Tuesday, 7 September 2021
|
|
| Why Adaptimmune Therapeutics Stock Is Bolting Higher Today | |
Monday, 21 June 2021
|
|
| 2 Biotech Penny Stocks That Are Vastly Superior Investments to Dogecoin | |
Thursday, 20 May 2021
|
|
| Why Adaptimmune Therapeutics Crushed the Market Today | |
| Cancer Biotechs Are on the Move in Advance of Big Conference | |
Friday, 16 October 2020
|
|
| Why Adaptimmune Therapeutics Stock Is Sinking Today | |
Tuesday, 11 August 2020
|
|
| All You Need to Know About Adaptimmune Therapeutics PLC Rating Upgrade to Buy | |
Monday, 10 August 2020
|
|
| Announcing: Adaptimmune Therapeutics Stock Soared An Exciting 367% In The Last Year | |
| Did The Underlying Business Drive Adaptimmune Therapeutics' Lovely 367% Share Price Gain? | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| Cintia Piccina Chief Commercial Officer | Sale 18 Jun 2024 | $22,814 |
| Adrian Rawcliffe Chief Executive Officer | Sale 16 Jan 2024 | $27,569 |
| Elliot Norry Chief Medical Officer | Sale 16 Jan 2024 | $14,188 |
| John Lunger Chief Patient Supply Officer | Sale 16 Jan 2024 | $15,957 |
| William C Jr Bertrand Chief Operating Officer | Sale 16 Jan 2024 | $16,512 |
| William C Jr Bertrand Chief Operating Officer | Sale 11 Jan 2024 | $7,845 |
| John Lunger Chief Patient Supply Officer | Sale 11 Jan 2024 | $7,845 |
| Elliot Norry Chief Medical Officer | Sale 11 Jan 2024 | $10,037 |
| Adrian Rawcliffe Chief Executive Officer | Sale 11 Jan 2024 | $24,822 |
| Adrian Rawcliffe Chief Executive Officer | Sale 1 Sep 2023 | $1,874 |
| John Lunger Chief Patient Supply Officer | Sale 1 Aug 2023 | $2,817 |
Powered by
Robintrack.
| Insider | Age | Since | Compensation |
|---|---|---|---|
| James Noble (61) Non-Executive Director since 2019 | 61 | 2019 | $2,821,740 |
| Adrian Rawcliffe (48) Chief Executive Officer and Director since 2019 | 48 | 2019 | $2,148,260 |
| William Bertrand (55) Chief Operating Officer since 2017 | 55 | 2017 | $1,369,510 |
| Helen Tayton-Martin (53) Chief Business Officer since 2017 | 53 | 2017 | $1,355,090 |
| Adrian G. Rawcliffe (49) CEO, Principal Accounting Officer, and Director | 49 | $986,256 | |
| Dr. Helen Katrina Tayton-Martin MBA, Ph.D. (54) Co-Founder and Chief Bus. Officer | 54 | $703,666 | |
| William C. Bertrand Jr. (56) Chief Operating Officer | 56 | $693,452 | |
| Gavin Hilary James Wood BA (Hons), ACA (51) Chief Financial Officer | 51 | $577,643 | |
| David Mott (54) Non-Executive Independent Chairman of the Board since 2017 | 54 | 2017 | $129,794 |
| Tal Zvi Zaks (54) Non-Executive Independent Director since 2016 | 54 | 2016 | |
| Elliott Sigal (68) Non-Executive Independent Director since 2014 | 68 | 2014 | |
| John Furey (55) Non-Executive Independent Director since 2018 | 55 | 2018 | |
| Barbara Duncan (55) Non-Executive Independent Director since 2016 | 55 | 2016 | |
| Ali Behbahani (43) Non-Executive Independent Director since 2014 | 43 | 2014 | |
| Lawrence Alleva (70) Non-Executive Independent Director since 2015 | 70 | 2015 | |
| John Lunger (51) Chief Patient Supply Officer since 2019 | 51 | 2019 | |
| Elliot Norry (57) Senior Vice President and Chief Medical Officer since 2020 | 57 | 2020 | |
| Gavin Wood (50) Chief Financial Officer since 2020 | 50 | 2020 | |
| Dr. Arundathy Nirmalini Pandite M.B.A., M.D. (62) Sr. VP of Clinical Devel. | 62 | ||
| Dr. Rafael G. Amado (57) Pres of R and Director | 57 | ||
| Sébastien Desprez | |||
| Margaret Henry | |||
| Dr. Juli P. Miller Ph.D. |
adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
- Health Care > Biotechnology
- Adaptimmune Therapeutics Plc, 60 Jubilee Avenue, Abingdon OX14 4RX, United Kingdom
- 44 12 3543 0000
- Investor relations
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $143.528 | $147.017 | |||
| Short term investments | $2.982 | $2.947 | |||
| Net receivables | $8.404 | $0.821 | |||
| Inventory | |||||
| Total current assets | $186.903 | $207.552 | |||
| Long term investments | |||||
| Property, plant & equipment | $67.725 | $71.708 | |||
| Goodwill & intangible assets | $0.524 | $0.33 | |||
| Total noncurrent assets | $71.107 | $75.064 | |||
| Total investments | $2.982 | $2.947 | |||
| Total assets | $258.01 | $282.616 | |||
| Current liabilities | |||||
| Accounts payable | $6.587 | $8.128 | |||
| Deferred revenue | $178.889 | $178.033 | |||
| Short long term debt | $5.25 | $5.384 | |||
| Total current liabilities | $66.411 | $72.788 | |||
| Long term debt | $18.442 | $19.851 | |||
| Total noncurrent liabilities | $167.224 | $170.315 | |||
| Total debt | $23.692 | $25.235 | |||
| Total liabilities | $233.635 | $243.103 | |||
| Stockholders' equity | |||||
| Retained earnings | -$1,071.676 | -$1,023.173 | |||
| Other stockholder equity | -$2.72 | -$3.748 | |||
| Total stockholder equity | $24.375 | $39.513 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $147.017 | $109.602 | ||
| Short term investments | $2.947 | $96.572 | ||
| Net receivables | $0.821 | $7.435 | ||
| Inventory | ||||
| Total current assets | $207.552 | $255.37 | ||
| Long term investments | ||||
| Property, plant & equipment | $71.708 | $71.535 | ||
| Goodwill & intangible assets | $0.33 | $0.442 | ||
| Total noncurrent assets | $75.064 | $73.546 | ||
| Total investments | $2.947 | $96.572 | ||
| Total assets | $282.616 | $328.916 | ||
| Current liabilities | ||||
| Accounts payable | $8.128 | $4.753 | ||
| Deferred revenue | $178.033 | $184.412 | ||
| Short long term debt | $5.384 | $2.728 | ||
| Total current liabilities | $72.788 | $64.501 | ||
| Long term debt | $19.851 | $20.349 | ||
| Total noncurrent liabilities | $170.315 | $182.537 | ||
| Total debt | $25.235 | $23.077 | ||
| Total liabilities | $243.103 | $247.038 | ||
| Stockholders' equity | ||||
| Retained earnings | -$1,023.173 | -$909.302 | ||
| Other stockholder equity | -$3.748 | -$0.875 | ||
| Total stockholder equity | $39.513 | $81.878 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $5.678 | $0.231 | |||
| Cost of revenue | |||||
| Gross profit | $5.678 | $0.231 | |||
| Operating activities | |||||
| Research & development | $35.207 | $33.208 | |||
| Selling, general & administrative | $19.732 | $16.879 | |||
| Total operating expenses | $54.939 | $50.087 | |||
| Operating income | -$49.261 | -$49.856 | |||
| Income from continuing operations | |||||
| EBIT | -$47.977 | -$48.573 | |||
| Income tax expense | $0.526 | -$0.656 | |||
| Interest expense | |||||
| Net income | |||||
| Net income | -$48.503 | -$47.917 | |||
| Income (for common shares) | -$48.503 | -$47.917 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $60.281 | $27.148 | ||
| Cost of revenue | ||||
| Gross profit | $60.281 | $27.148 | ||
| Operating activities | ||||
| Research & development | $126.509 | $127.726 | ||
| Selling, general & administrative | $73.513 | $63.387 | ||
| Total operating expenses | $200.022 | $191.113 | ||
| Operating income | -$139.741 | -$163.965 | ||
| Income from continuing operations | ||||
| EBIT | -$112.535 | -$162.959 | ||
| Income tax expense | $1.336 | $2.497 | ||
| Interest expense | ||||
| Net income | ||||
| Net income | -$113.871 | -$165.456 | ||
| Income (for common shares) | -$113.871 | -$165.456 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | -$48.503 | -$47.917 | |||
| Operating activities | |||||
| Depreciation | $2.83 | $2.871 | |||
| Business acquisitions & disposals | |||||
| Stock-based compensation | $3.102 | $3.081 | |||
| Total cash flows from operations | -$31.95 | -$14.676 | |||
| Investing activities | |||||
| Capital expenditures | -$0.102 | -$0.827 | |||
| Investments | $68.813 | ||||
| Total cash flows from investing | -$0.358 | $68.197 | |||
| Financing activities | |||||
| Dividends paid | |||||
| Sale and purchase of stock | $29.235 | $0.074 | |||
| Net borrowings | |||||
| Total cash flows from financing | $29.235 | $0.074 | |||
| Effect of exchange rate | -$0.416 | $0.35 | |||
| Change in cash and equivalents | -$3.489 | $53.945 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | -$113.871 | -$165.456 | ||
| Operating activities | ||||
| Depreciation | $9.84 | $6.075 | ||
| Business acquisitions & disposals | $45.264 | |||
| Stock-based compensation | $11.773 | $18.24 | ||
| Total cash flows from operations | -$140.88 | -$141.769 | ||
| Investing activities | ||||
| Capital expenditures | -$4.681 | -$29.496 | ||
| Investments | $135.03 | $118.877 | ||
| Total cash flows from investing | $176.538 | $89.137 | ||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.88 | $12.867 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.88 | $12.867 | ||
| Effect of exchange rate | $0.877 | -$2.299 | ||
| Change in cash and equivalents | $37.415 | -$42.064 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Ecor1 Capital |
Opened
|
27,404,070 | $43,298,431 |
| 2024 Q1 | Morgan Stanley |
-80.92%
|
373,281 | $589,783 |
| 2024 Q1 | Mpm Asset Management |
-11.64%
|
5,555,461 | $8,777,628 |
| 2024 Q1 | Redmile |
Opened
|
715,607 | $1,130,659 |
| 2024 Q1 | Long Focus Capital Management |
-2.54%
|
10,684,233 | $16,881,088 |
| 2024 Q1 | Ubs Ag |
+696.57%
|
196,696 | $310,780 |
| 2024 Q1 | Gsa Capital Partners LL.P. |
-27.25%
|
370,179 | $585 |
| 2024 Q1 | Blackrock |
+61.31%
|
289,688 | $457,707 |
| 2024 Q1 | Lpl |
Opened
|
108,856 | $171,992 |
| 2024 Q1 | Goldman Sachs Group Inc |
+573.15%
|
107,562 | $169,948 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Matrix Capital Management , L.P. | 25.20% | 38,974,185 | |
| Ecor1 Capital | 17.72% | 27,404,070 | |
| Nea Management | 11.04% | 17,079,779 | |
| Baker Bros. Advisors L.P. | 7.09% | 10,969,282 | |
| Long Focus Capital Management | 6.91% | 10,684,233 | |
| Mpm Asset Management | 3.59% | 5,555,461 | |
| Bioimpact Capital | 3.29% | 5,095,912 | |
| Pfm Health Sciences, L.P. | 3.13% | 4,843,510 | |
| Bank Of America Corp de/ | 3.02% | 4,667,787 | |
| Rock Springs Capital Management L.P. | 1.57% | 2,425,468 |
Sign up